Xiaohua Wu

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)

Kathleen N. Moore, Michael A. Bookman, Jalid Sehouli et al. · Journal of Clinical Oncology · 2021 · 406 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

Shannon N. Westin, Kathleen N. Moore, Hye Sook Chon et al. · Journal of Clinical Oncology · 2023 · 331 citations · Full text

Medicine, Oncology, Pharmacology +12

Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆

Xiaohua Wu, Jianqing Zhu, Rutie Yin et al. · Annals of Oncology · 2021 · 206 citations

Medicine, Oncology, Pharmacology +15

Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial

Xiangyu Gao, Nong Xu, Ziyu Li et al. · The Lancet Oncology · 2023 · 197 citations

Pharmacy, Oncology, Pharmacology +16

FBW7 suppresses ovarian cancer development by targeting the N6-methyladenosine binding protein YTHDF2

Fei Xu, Jiajia Li, Mengdong Ni et al. · Molecular Cancer · 2021 · 139 citations · Full text

Medicine, Molecular Biology, Oncology +17